<%=targetData.preHeaderText%>
|
|
|
Recognize Chronic Granulomatous Disease in Your Patients With Subcutaneous Abscesses
|
|
Recognize Chronic Granulomatous Disease in Your Patients With Subcutaneous Abscesses
|
|
|
|
Dear
<% if ( recipient.NAME_PREFIX != '' ) { %><%= recipient.NAME_PREFIX %> <%= recipient.lastName %><%} else { %>Dr. <%= recipient.lastName %><%} %>,
|
|
|
Skin and soft tissue abscesses, including subcutaneous abscess and suppurative adenitis, may be the first symptoms of chronic granulomatous disease (CGD).1,2 These infections are often caused by Staphylococcus aureus, but they can be caused also by Serratia or Klebsiella species; frequently appear in the perianal region; and are more severe in X-linked CGD compared with autosomal recessive CGD.1,3,4 Locate a CGD specialist who may be experienced in diagnosing CGD.
|
|
|
If you suspect CGD in your patient, order a dihydrorhodamine (DHR) test to help confirm a diagnosis, distinguish between X-linked and autosomal recessive forms of CGD, and detect carrier status.2
|
|
|
|
Hiding on the X: Rethinking Perceptions of Carriers of X-Linked CGD
|
|
|
Watch the 2022 Clinical Immunology Society Dinner Symposium presentation to learn more about identifying and monitoring X-linked carriers.
|
|
|
References: 1. Bennett N, Maglione PJ, Wright BL, Zerbe C. Infectious complications in patients with chronic granulomatous disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S12-S17. 2. Leiding JW, Holland SM. Chronic granulomatous disease. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. GeneReviews®. Seattle, WA: University of Washington, Seattle; 1993-2022. 3. Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin Mol Allergy. 2011;9(1):10-24. 4. Winkelstein JA, Marino MC, Johnston RB, et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore). 2000;79(3):155-169.
|
|
|
|
1 Horizon Way, Deerfield, IL 60015
|
|
|
CGD PATHWAYS and the HORIZON logo are trademarks owned by or licensed to Horizon.
|
© 2023 Horizon Therapeutics plc DA‑UNBR‑US‑02019 09/23
|
|
|
|
|